131 completed, 28 terminated, 15 unknown, 10 recruiting. 92 Phase 2, 65 Phase 1, 25 Phase 3, 8 Not applicable, 2 Early Phase 1.
Follow Leukemia, Monocytic, Acute: new trials by email Literature Review of Leukemia, Monocytic, Acute trials Research Report on Leukemia, Monocytic, Acute
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Halt Aging in Survivors of Blood Cancers Behavioral Coaching Intervention, Virtual Exercise Platform - Hematological Malignancy, Leukemia | Not applicable | Recruiting | University of Nebraska | 180 | 2026-04-09 | 2026-07-01 |
| Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia CACAG+VEN, 3+7 - Acute Monocytic Leukemia | Phase 2 | Recruiting | Chinese PLA General Hospital | 204 | 2025-09-01 | 2026-04-06 |
| A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) STX-0712 - Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia (CMML) | Phase 1 | Recruiting | Solu Therapeutics, Inc | 105 | 2025-03-13 | 2026-02-09 |
| Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Monocytic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | OHSU Knight Cancer Institute | 40 | 2025-01-03 | 2026-09-16 |
| Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia Venetoclax, Azacitidine, Mitoxantrone - Leukemia, Myeloid Leukemia | Phase 1 | Recruiting | University of Colorado, Denver | 30 | 2024-07-21 | 2026-01-15 |
| Integrated Actionable Aging Assessment for Cancer Patients Pilot Assessment tool IA3-CP with SDoH, Assessment tool IA3-CP without SDoH - Breast Cancer, Hodgkin Lymphoma | Not applicable | Active not recruiting | University of Colorado, Denver | 35 | 2024-03-01 | 2025-09-15 |
| Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia Chidamide, Azacitidine, Venetoclax - Acute Monocytic Leukemia, Newly Diagnosed | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 92 | 2022-03-01 | 2025-11-21 |
| Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation Enasidenib mesylat dose escalation - Leukemia, Leukemia, Myeloid | Phase 1 / Phase 2 | Completed | Tian Yi Zhang | 17 | 2022-01-12 | 2026-09-03 |
| Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children Cladribine, G-CSF, Cytarabine - Leukemia, Monocytic, Acute, Pediatric AML | Phase 2 / Phase 3 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 43 | 2021-12-01 | 2023-07-27 |
| FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia Daratumumab/rHuPH20, FT538, Fludarabine - Acute Myeloid Leukemia, Myeloid Leukemia | Phase 1 | Completed | Masonic Cancer Center, University of Minnesota | 9 | 2021-11-03 | 2024-10-24 |
| CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine - Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 1 | 2021-08-09 | 2024-05-23 |
| Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5) anti-ILT3 CAR-T - AML M4, AML M5 | Early Phase 1 | Unknown | Carbiogene Therapeutics Co. Ltd. | 25 | 2021-03-03 | 2021-03-23 |
| CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients Liposome-encapsulated Daunorubicin-Cytarabine, Cladribine, Cytarabine - Acute Myeloid Leukemia, Myeloid Neoplasm | Phase 2 | Completed | Fred Hutchinson Cancer Center | 60 | 2020-05-27 | 2026-06-29 |
| Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms Cladribine, Cytarabine, Recombinant Granulocyte Colony-Stimulating Factor - Myeloid Neoplasm, Recurrent Acute Myeloid Leukemia | Phase 1 | Terminated | University of Washington | 13 | 2020-05-08 | 2023-12-28 |
| Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms Decitabine, Ruxolitinib, Fedratinib - Acute Myeloid Leukemia, Essential Thrombocythemia | Phase 2 | Recruiting | University of Washington | 25 | 2020-03-24 | 2026-09-17 |
| Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS Decitabine, Ruxolitinib, Donor Lymphocyte Infusion (DLI) - Acute Myeloid Leukemia, Myeloid and Monocytic Leukemia | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 14 | 2020-02-17 | 2023-11-07 |
| Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) Total-Body Irradiation, Thiotepa, Fludarabine - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 120 | 2019-11-19 | 2026-10-20 |
| 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Cyclophosphamide, Total-Body Irradiation - Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 30 | 2019-07-10 | 2026-06-22 |
| Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia Gemtuzumab Ozogamicin, Quality-of-Life Assessment, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 2 | Recruiting | University of Washington | 36 | 2018-11-30 | 2026-08-13 |
| Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients Intravenous (IV) and oral Vitamin C - Lymphoid Leukemia, Myeloid Leukemia | Phase 2 | Completed | Virginia Commonwealth University | 61 | 2018-10-01 | 2023-11-07 |
Showing 20 of 193. Sign in to see all of them.
Leukemia, Myeloid, Acute (179) · Leukemia, Myelomonocytic, Acute (166) · Leukemia, Erythroblastic, Acute (162) · Leukemia, Megakaryoblastic, Acute (158) · Congenital Abnormalities (126) · Leukemia (101) · Leukemia, Basophilic, Acute (53) · Leukemia, Eosinophilic, Acute (53) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (33) · Leukemia, Promyelocytic, Acute (28) · Myelodysplastic Syndromes (27) · Blast Crisis (23) · Anemia, Refractory, with Excess of Blasts (21) · Leukemia, Myelomonocytic, Chronic (21)
Hematologic Diseases (193) · Hemic and Lymphatic Diseases (193) · Neoplasms by Histologic Type (193) · Neoplasms (192) · Leukemia, Myeloid (187) · Bone Marrow Diseases (171) · Myeloproliferative Disorders (149) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (126) · Leukemia (92) · Chronic Disease (41) · Disease Attributes (41) · Pathologic Processes (41) · Pathological Conditions, Signs and Symptoms (41) · Immune System Diseases (38) · Immunoproliferative Disorders (38)
Cytarabine (84) · Daunorubicin (31) · Etoposide (31) · Idarubicin (26) · Mitoxantrone (26) · Filgrastim (24) · Busulfan (20) · Peripheral Blood Stem Cell Transplantation (19) · Cyclophosphamide (17) · fludarabine phosphate (15) · Gemtuzumab (14) · Azacitidine (11) · tipifarnib (11) · Clofarabine (10) · Methotrexate (10)
National Cancer Institute (NCI) (44) · Fred Hutchinson Cancer Center (13) · SWOG Cancer Research Network (11) · European Organisation for Research and Treatment of Cancer - EORTC (8) · Roswell Park Cancer Institute (8) · Case Comprehensive Cancer Center (7) · Alliance for Clinical Trials in Oncology (6) · Eastern Cooperative Oncology Group (6) · Children's Oncology Group (5) · ECOG-ACRIN Cancer Research Group (4) · Masonic Cancer Center, University of Minnesota (4) · Memorial Sloan Kettering Cancer Center (4) · Northwestern University (4) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4) · University of Washington (4)
United States (149) · Canada (13) · France (11) · Italy (9) · Belgium (8) · Netherlands (8) · United Kingdom (8) · Germany (5) · China (4) · Croatia (4) · Israel (4) · Austria (3) · Portugal (3) · Puerto Rico (3) · Switzerland (3)
Judith Karp (6) · Roland Walter (5) · Sergio Amadori, MD (5) · Anjali Advani, MD (4) · B. Smith (4) · Alan K. Burnett, MD, FRCP (3) · Bruno de Medeiros (3) · Jerry Radich, MD (3) · Martin S. Tallman, MD (3) · Meir Wetzler, MD (3) · Thomas R. Chauncey, MD, PhD (3) · Anthony S. Stein, MD (2) · B. Douglas Smith, MD (2) · Bayard L. Powell, MD (2) · Bonny L. Johnson, RN, MSN (2)
PMID 24383844, PMID 25527568, PMID 31375516, PMID 36184192, PMID 29926156, PMID 30523055, PMID 32499241, PMID 37267439, PMID 11331327, PMID 11585760, PMID 12750167, PMID 15339678, PMID 15514371, PMID 15761020, PMID 16275934, PMID 16484584, PMID 16670265, PMID 16932345, PMID 17315155, PMID 17339189, PMID 17562873, PMID 17640728, PMID 18571721, PMID 19010875, PMID 19092853, PMID 19109557, PMID 19242495, PMID 19289999, PMID 19291085, PMID 19710500, PMID 19794082, PMID 19804455, PMID 19826132, PMID 20038732, PMID 20460644, PMID 20522709, PMID 20716770, PMID 20952518, PMID 21239698, PMID 21393334, PMID 21551228, PMID 21791475, PMID 22001391, PMID 22133771, PMID 22627678, PMID 22733022, PMID 23256542, PMID 23443507, PMID 23471307, PMID 23547838
U01CA070095 (14), U10CA032102 (14), P30CA006973 (10), P30CA015704 (8), U10CA031946 (8), P30CA043703 (5), N01CM62204 (4), U10CA021115 (4), U10CA180821 (4), P30CA016056 (3), P30CA072720 (3), P30CA124435 (3), N01CM00100 (2), N01CM62202 (2), P30CA016672 (2)